Navigation Links
Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril

NANTONG, China, Jan. 25 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC Bulletin Board: SNBP) is pleased to announce that its production facility for solid dosage Perindopril has passed the required Chinese State Food and Drug Administration (SFDA) inspection and is now approved for production and marketing.

Sinobiopharma had received SFDA approval for its formulation of Perindopril, the first version of the drug to be developed in China, in April 2009.  SFDA regulations require that drug makers conduct large-scale production of at least three batches of a newly approved drug in a Good Manufacturing Practice (GMP) certified production facility. SFDA officials inspect the production process, the application of GMP standards, and conducted a full test of randomly picked samples of the drug. Sinobiopharma successfully met all the requirements and now has received approval to distribute the drug throughout China.

The Company believes its formulation of Perindopril is the latest generation worldwide of the product, which is part of a class of medications known as angiotensin-converting enzyme (ACE) inhibitors. These medications are used alone or in combination with other medications to treat high blood pressure.  Perindopril allows blood to flow more smoothly by preventing the production of certain natural chemicals that constrict blood vessels.  Every year, US$3.7 billion is spent on the treatment of hypertension in China.  Sinibiopharma's Perindopril will be marketed under the trade name YiTai in China.  

"We believe that YiTai is a first-to-market drug in China and therefore enjoys the benefit of having a government sanctioned price premium as well as certain exclusive marketing rights to hospitals," said Dr. Lequn Lee Huang, CEO of the Company. "The market for anti-hypertensives in China is huge, but highly fragmented. Sinobiopharma's YiTai is well positioned to capture substantial market share quickly."

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.


This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.

SOURCE Sinobiopharma, Inc.

SOURCE Sinobiopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
2. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
3. Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World
4. Offers Insight Into Two Growing Chinese Pharmaceutical Firms
5. Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
7. Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
8. Reportlinker Adds Brazil, Russian, Indian and Chinese Markets for Endoscopic Devices 2009 (4 Countries)
9. Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs
10. Reportlinker Adds Chinese Markets for Respiratory Drugs
11. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
Post Your Comments:
(Date:11/24/2015)... 2015 Sectra (STO: SECT B) ... into a multi-year agreement to deploy Breast Imaging ... provide the Breast Center a future-proof platform capable of ... SECT B) announces that Breast Center of Acadiana ... Breast Imaging PACS in its two freestanding imaging centers. This ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... 2015 iRhythm Technologies, Inc. , a leading digital ... that it will participate in the 27th Annual Piper Jaffray Healthcare ... York, NY . Kevin King , Chief Executive ... 2015 at 8:50am ET. --> ... --> . --> iRhythm is a ...
Breaking Medicine Technology:
(Date:11/24/2015)... Peoria, IL (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey ... His new venture, Koala Center for Sleep Disorders, provides treatment for snoring and ... dentists who have opened a Koala Center for Sleep Disorders in the US, one of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Bibliomotion is thrilled to ... Me about Reinvention and Diversity by Nancy M. Schlichting, Chief Executive Officer ... failing to adequately address the needs of patients and their families, shaped my desire ...
(Date:11/24/2015)... ... November 24, 2015 , ... World Patent ... Blending, a household invention that revolutionizes the vending machine industry by providing healthy ... is worth $2 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... announces Fragrance by Marcelle, a cosmetic invention which offers a combination of natural ... Market in the US is worth $3 billion annually," says Scott Cooper, CEO ...
(Date:11/24/2015)... ... , ... “I am so thrilled, as a newbie here, to leave a mark for the ... School Lounge Makeover® from California Casualty . Stephanie is in her fifth year teaching ... longer tenure. , “This is such an amazing school and we deserve a space where ...
Breaking Medicine News(10 mins):